Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.
Metoclopramide: Stronger warnings on risk of abnormal muscle movements
- Starting date:
- July 20, 2011
- Posting date:
- July 20, 2011
- Type of communication:
- Information Update
- Source of recall:
- Health Canada
- Product Safety, Labelling and Packaging
- General Public
- Identification number:
Health Canada is informing health professionals and consumers that the labelling information for the drug metoclopramide is being updated to include stronger warnings on the risk of a movement disorder known as "tardive dyskinesia." The disorder is characterized by uncontrollable muscle movements, mainly in the face. The risk increases with longer treatment and is higher in the elderly, especially elderly women.
Metoclopramide, available in Canada since 1975, is a prescription drug. It is most commonly used to treat digestive problems associated with a stomach that empties too slowly. It works by helping speed the movement of food through the stomach and intestines. (See below for a list of metoclopramide drugs in Canada.)
Tardive dyskinesia is a known side effect associated with metoclopramide. The current prescribing information contains information on this risk. Health Canada is working with the Canadian manufacturers to include stronger, more detailed warnings in the drug labelling that contain the following information:
- Tardive dyskinesia may develop in patients treated with metoclopramide. The elderly, especially elderly women, appear to be at increased risk.
- The risk appears to increase with treatment length and the total amount of drug taken.
- Tardive dyskinesia is more likely to be irreversible with long-term treatment (over 12 weeks).
- Less frequently, tardive dyskinesia can develop with short term treatment at low doses; in these cases, the symptoms are more likely to disappear either partially or completely over time, once treatment has been stopped.
- Tardive dyskinesia may not be easy to recognise in its early stages.
- Metoclopramide treatment beyond 12 weeks should be avoided, unless the benefit is judged to outweigh the risk.
Tardive dyskinesia usually appears as involuntary movements of the tongue, face, mouth or jaw. These movements can include lip smacking, chewing, or puckering, or sticking out of the tongue. Sometimes, movements can include the torso or limbs, such as leg shaking. There are no known treatments for tardive dyskinesia once it has become established.
Health care professionals are reminded that metoclopramide is not authorized in Canada for the following: treatment of hiccups, diabetic gastroparesis (partial paralysis of the stomach), nausea and vomiting in pregnancy, or for symptoms of bloating or constipation associated with eating disorders.
Metoclopramide drugs currently marketed in Canada
Metoclopramide is available in various strengths and forms, including as a solution for injection, or as liquid or tablets that can be taken by mouth. It is sold under generic names only.
|Apotex Incorporated||Apo-metoclop tab 10 mg|
|Apotex Incorporated||Apo-metoclop tab 5 mg|
|Sandoz Canada Incorporated||Metoclopramide Hydrochloride Injection|
|Bioniche Pharma (Canada) Ltd.||Metoclopramide Hydrochloride Injection HS|
|Omega Laboratories Ltd.||Metoclopramide Omega Injection|
|Pro Doc Limitée||Metoclopramide Tab 10 mg|
|Pro Doc Limitée||Metoclopramide Tab 5 mg|
|Nu-Pharm Inc.||Nu-Metoclopramide-Tab 10 mg|
|Nu-Pharm Inc.||Nu-Metoclopramide-Tab 5 mg|
|Pharmascience Inc.||PMS-Metoclopramide-Tab 5 mg|
|Pharmascience Inc.||PMS-Metoclopramide-Tab 10 mg|
|Pharmascience Inc.||PMS-Metoclopramide-Oral Solution|
For more information
How to report side effects to health products
To report suspected side effects to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or complete a Canada Vigilance Reporting Form and send to us using one of these methods:
- Fax: 1-866-678-6789
- Internet: MedEffect Canada
Mail: Canada Vigilance Program
Marketed Health Products Directorate
Ottawa, ON, Address Locator 0701E
- Date modified: